Program Overview
KEMRI/USAMRD-K
The Walter Reed Project
Military HIV Research Program - Kenya

United States Army Medical Research Directorate-Kenya
Kericho Field Station

Samwel Chirchir (HJF-MRI)

Jun 15, 2016
KERICHO
Outline

- Program Overview, Operations, and Achievements
- Primary Mission: Vaccine Focus
- Secondary Focus: Therapeutics and Operational Research
- Laboratories
- President’s Emergency Plan for AIDS Relief (PEPFAR)
2016 Program Overview

Primary Mission
- Vaccines
- Cohorts

Secondary Mission
- Health
- Economic
- Research
- Non-HIV
- Therapeutics & Operational

- Treatment
- Prevention
- HIV Care
- Mitigation

Operational & Non-Operational
Kericho Program Operational Relationships

Primary HIV Research Program

PEPFAR Program

Prevention, care, & treatment

Recruitment

Bi-directional leveraging

Microbiology Lab

Kericho – USAMRD-K’s primary HIV Site, part of WRAIR Division of Retrovirology Int’l network (MHRP)

Covering research recruitment / catchment area and needs of larger southern Rift Valley Province
USAMRD-K Program Objectives (Kericho)

PRIMARY OBJECTIVES

1. Evaluate HIV candidate vaccines to support the development of a globally effective HIV vaccine to protect U.S. military service members, allied forces and the world community.

2. Develop Kenyan leaders to become internationally recognized clinical research experts.
USAMRD-K Program Objectives (Kericho)

SECONDARY OBJECTIVES

1. Function as a comprehensive HIV research center conducting both interventional (vaccine and therapeutic) and operational research.

2. Support the U.S President’s Emergency Plan For AIDS Relief (PEPFAR) by providing comprehensive HIV prevention, care and treatment in South Rift Valley (SRV) Province of Kenya.
Kericho/WRP Program Milestones

- Site established
- Begin cohort studies
  - 1999
- Renovated maternal clinic
  - 2003
- PEPFAR initiated
  - 2004
- Opened 1st integrated TB/HIV clinic
  - 2005
- Therapeutic studies opens
  - 2006
- Complete first and largest vaccine study out of Nairobi
  - 2007
- First CAP-certified lab in Kenya
  - 2008
- Became site for NIH’s ACTG
  - 2008
- Micro lab launches first study
  - 2010
- DNA/MVA vaccine study begins
  - June 2012
- Became site for NICHD’s IMPAACT
  - 2014
- Begin polio vaccine study
  - 2015
PEPFAR Milestones (APR 2015)

- HTC: >2.8M tested
- PMTCT: >792k mothers
- OP: >338k
- AB Messages: ~710k
- VMMC: >100k
- OVC: >26k orphans
- ART: >79k patients
- Care & Support: >29k patients
- TB/HIV: >21k co-infected patients
- Prevention, Care, and Treatment: >44k patients
Clinical Research Center Clinic

Kericho CRC clinic.
Kericho Field Station Staff